|
|
Volumn 42, Issue 4, 2014, Pages 53-58
|
|
Is glycemic control of the critically ill cost-effective?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
GLUCOSE BLOOD LEVEL;
INSULIN;
ANALYSIS;
COST BENEFIT ANALYSIS;
COST CONTROL;
CRITICAL ILLNESS;
CROSS INFECTION;
ECONOMICS;
GLUCOSE BLOOD LEVEL;
GLYCEMIC INDEX;
HEALTH CARE COST;
HUMAN;
HYPERGLYCEMIA;
INTENSIVE CARE UNIT;
LENGTH OF STAY;
OUTCOME ASSESSMENT;
PROSPECTIVE STUDY;
STATISTICS AND NUMERICAL DATA;
BLOOD GLUCOSE;
COST SAVINGS;
COST-BENEFIT ANALYSIS;
CRITICAL ILLNESS;
CROSS INFECTION;
GLYCEMIC INDEX;
HEALTH CARE COSTS;
HUMANS;
HYPERGLYCEMIA;
HYPOGLYCEMIC AGENTS;
INSULIN;
INTENSIVE CARE UNITS;
LENGTH OF STAY;
OUTCOME ASSESSMENT (HEALTH CARE);
PROSPECTIVE STUDIES;
|
|
EID: 84922532143
PISSN: 21548331
EISSN: None
Source Type: Journal
DOI: 10.3810/hp.2014.10.1142 Document Type: Article |
|
Times cited : (7)
|
|
References (0)
|